Primary source: Inspections and Compliance
The FDA issued immediately-in-effect guidance detailing temporary regulatory and enforcement priorities regarding compounded starter parenteral nutrition drug products for neonates, addressing supply gap concerns.
This regulatory action is crucial as it seeks to maintain access to life-saving nutrition for vulnerable newborns during a potential supply disruption, ensuring patient care is not compromised.
Healthcare providers and compounding facilities should implement the new temporary policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to ensure compliance and access to essential nutrition products.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Healthcare providers and compounding facilities should implement the new temporary policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to ensure compliance and access to essential nutrition products.
On September 4, 2026, the FDA announced immediate guidance to support the compounding of certain starter parenteral nutrition products to prevent supply disruptions. This action aims to ensure continued access for vulnerable patients, particularly premature and critically ill newborns who require nutrition via IV due to their inability to feed orally. The guidance details temporary regulatory and enforcement priorities for state-licensed pharmacies and outsourcing facilities compounding these essential drugs.
What changed: The FDA issued immediately-in-effect guidance detailing temporary regulatory and enforcement priorities regarding compounded starter parenteral nutrition drug products for neonates, addressing supply gap concerns.
Why it matters: This regulatory action is crucial as it seeks to maintain access to life-saving nutrition for vulnerable newborns during a potential supply disruption, ensuring patient care is not compromised.
Practical implication: Healthcare providers and compounding facilities should implement the new temporary policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to ensure compliance and access to essential nutrition products.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.
Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.
Regulatory compliance workflows involving the Dengue Tetravalent Vaccine outside the EU need to incorporate the EMA's positive opinion concerning its use in individuals aged 4 to 60.
Regulatory intelligence processes must update reporting timelines and workflows to incorporate the new PSUSA findings for exemestane.
